

DAHLSTROM, VERA

For Surgery Use ☐ Urgent ☐ Ring Patient ☐ Make Appointment ☐ Note in Chart ☐ File ☐

Patient KELLY, ROBERT

UR No.

Patient Address 2 DIAMANTINA GARDENS WINTON QLD 4735

Sex M Age 79 years DOB 23/12/1945

Report For DAHLSTROM, VERA

Ref. by/copy to DAHLSTROM, VERA

Requested	20/06/2025	
Collected	20/06/2025	09:04 AM
Reported	23/06/2025	11:58 AM

CUMULATIVE VITAMIN B12 AND FOLATE ASSAYS

Date	20/06/25
Time	09:04
Lab No	92168535

Active B12	66 pmol/L	(> 35)
------------	-----------	--------

Comment:
92168535

Holo TC Assay:
No current vitamin B12 deficiency.

Methodology:
B12 and Active B12 (HoloTC) assays performed on Siemens Atellica analyser.

For Doctor clinical enquiries, please contact Dr Peter Davidson 07 3121 4444.
Patients should contact their referring doctor in regard to this result.

Pathology Report

DAHLSTROM, VERA

For Surgery Use

Urgent

Ring Patient

Make Appointment

Note in Chart

File

Patient

KELLY, ROBERT

UR No.

Patient Address

2 DIAMANTINA GARDENS WINTON QLD 4735

Sex

M

Age

79 years

DOB

23/12/1945

Requested

20/06/2025

Report For

DAHLSTROM, VERA

Collected

20/06/2025

09:04 AM

Ref. by/copy to

DAHLSTROM, VERA

Reported

23/06/2025

11:58 AM

Serum Zinc

10

umol/L

(10-25)

Pathology Report

DAHLSTROM, VERA

For Surgery Use ☐ Urgent ☐ Ring Patient ☐ Make Appointment ☐ Note in Chart ☐ File ☐

Patient	KELLY, ROBERT	UR No.	
Patient Address	2 DIAMANTINA GARDENS WINTON QLD 4735		
Sex	M	Age	79 years
DOB	23/12/1945		
Report For	DAHLSTROM, VERA		
Ref. by/copy to	DAHLSTROM, VERA		
Requested	20/06/2025		
Collected	20/06/2025	09:04 AM	
Reported	23/06/2025	11:58 AM	

CUMULATIVE SERUM HIGH SENSITIVITY C-REACTIVE PROTEIN (CRP)

Date	20/06/25
Time	09:04
Lab No	92168535
CRP	4.6 mg/L (0.0-6.0)

C-reactive protein (CRP) is a non-specific indicator of tissue damage. Common causes of markedly increased CRP include infection, trauma, myocardial infarction, malignancy and inflammation.

In apparently healthy men and women who have an intermediate risk of cardiovascular disease, as assessed by major risk factors, CRP can identify a higher risk subgroup with CRP > 3 mg/L.

Range(mg/L)	Risk Estimate
Up to 1.0	Low
1.0 to 3.0	Average
3.1 to 10.0	High
Over 10.0	Assess for acute inflammation

In known, stable, coronary disease a CRP > 1 mg/L has shown increased risk.
 Reference: Circulation 2003;107:499-511 & 2007;115:1528-1536

Pathology Report

DAHLSTROM, VERA

For Surgery Use

Urgent

Ring Patient

Make Appointment

Note in Chart

File

Patient

KELLY, ROBERT

Patient Address

2 DIAMANTINA GARDENS WINTON QLD 4735

Sex

M

Age

79 years

DOB

23/12/1945

Report For

DAHLSTROM, VERA

Ref. by/copy to

DAHLSTROM, VERA

UR No.

Requested

20/06/2025

Collected

20/06/2025

09:04 AM

Reported

23/06/2025

11:58 AM

CUMULATIVE TRACE ELEMENTS

Date

20/06/25

Time

09:04

Lab No

92168535

Magnesium

0.8 mmol/L(0.7-1.1)

Pathology Report

DAHLSTROM, VERA

For Surgery Use ☐ Urgent ☐ Ring Patient ☐ Make Appointment ☐ Note in Chart ☐ File ☐

Patient **KELLY, ROBERT**

UR No.

Patient Address **2 DIAMANTINA GARDENS WINTON QLD 4735**

Sex **M** Age **79 years** DOB **23/12/1945**

Report For **DAHLSTROM, VERA**

Ref. by/copy to **DAHLSTROM, VERA**

Requested 20/06/2025
Collected 20/06/2025 09:04 AM
Reported 23/06/2025 11:58 AM

CUMULATIVE LIPID RISK REPORT

Date

20/06/25

Time

09:04

Lab No

92168535

FASTING

Target if
HIGH RISK

Total Cholesterol

3.3 mmol/L (below 4.0)

Triglycerides

1.1 mmol/L (below 2.0)

CHOLESTEROL FRACTIONS

HDL

1.17 mmol/L (above 1.0)

LDL (calculated)*

1.63 mmol/L (below 2.5)

Non-HDL cholesterol*

2.13 mmol/L (below 3.3)

Total/HDL ratio**

2.8

* Secondary prevention LDL and non-HDL cholesterol targets are lower.

** The ratio is for use with the cardiovascular risk calculator.

Web-search: "Australian cardiovascular risk calculator"

92168535 Treatment is recommended if clinically indicated or if calculated risk exceeds 15% absolute risk of CVD events over 5 years.

NVDPA 2012 **Target** ranges refer to **HIGH RISK PATIENTS**.

As of 7/3/22 LDL will no longer be measured routinely. LDL results will be calculated, in accordance with National harmonisation.

Pathology Report

DAHLSTROM, VERA

For Surgery Use ☐ Urgent ☐ Ring Patient ☐ Make Appointment ☐ Note in Chart ☐ File ☐

Patient **KELLY, ROBERT**
Patient Address **2 DIAMANTINA GARDENS WINTON QLD 4735**
Sex M Age 79 years DOB 23/12/1945
Report For DAHLSTROM, VERA
Ref. by/copy to DAHLSTROM, VERA

UR No.

Requested 20/06/2025
Collected 20/06/2025 09:04 AM
Reported 23/06/2025 11:58 AM

CUMULATIVE SERUM BIOCHEMISTRY

Date	20/06/25	
Time	09:04	
Lab No	92168535	
	FASTING	FASTING
Sodium	139 mmol/L	(137-147)
Potass.	4.8 mmol/L	(3.5-5.0)
Chloride	103 mmol/L	(96-109)
Bicarb	28 mmol/L	(25-33)
An.Gap	13 mmol/L	(4-17)
Gluc	5.1 mmol/L	(3.0-6.0)
Urea	5.3 mmol/L	(3.0-8.5)
Creat	74 umol/L	(60-140)
eGFR	83 mL/min	(over 59)
Urate	0.39 mmol/L	(0.12-0.45)
T.Bili	20 umol/L	(2-20)
Alk.P	73 U/L	(30-115)
GGT	26 U/L	(0-70)
ALT	17 U/L	(0-45)
AST	18 U/L	(0-41)
LD	238 U/L	(80-250)
Calcium	2.53 mmol/L	(2.15-2.60)
Corr.Ca	2.64 mmol/L	(2.15-2.60)
Phos	1.0 mmol/L	(0.8-1.5)
T.Prot	64 g/L	(60-82)
Alb	39 g/L	(35-50)
Glob	25 g/L	(20-40)
Chol	3.3 mmol/L	(3.6-7.3)
Trig	1.1 mmol/L	(0.3-2.2)
Lab No	92168535	
Date	20/06/25	

Pathology Report

DAHLSTROM, VERA

For Surgery Use ☐ Urgent ☐ Ring Patient ☐ Make Appointment ☐ Note in Chart ☐ File ☐

Patient **KELLY, ROBERT**

UR No.

Patient Address **2 DIAMANTINA GARDENS WINTON QLD 4735**

Sex **M** Age **79 years** DOB **23/12/1945**

Report For **DAHLSTROM, VERA**

Ref. by/copy to **DAHLSTROM, VERA**

Requested 20/06/2025
Collected 20/06/2025 09:04 AM
Reported 23/06/2025 11:58 AM

CUMULATIVE SERUM HOMOCYSTEINE

Date 20/06/25
Time 09:04
Lab No 92168535

Homocysteine + **24.4** umol/L (0.0-15.0)

92168535 This raised homocysteine concentration may be associated with an independent elevation of risk of vascular disease.

With this degree of elevation, the heterozygous state for a defect of transsulphuration (leading to raised homocysteine levels) is likely. However the elevation may be seen with renal impairment or a suboptimal dietary intake of folate or B12 or vitamin B6 (pyridoxine). Review of renal function or a four week trial of a multivitamin supplement may assist clarifying this.

Homocysteine Related Risk

Plasma level (umol/L)	Risk Average
Below 9.0	No increase
9.0 - 14.9	x 2
15.0 - 19.9	x 3
20.0 or greater	x 4.5

Risks approximated from New Eng J Med 1997 (337:230-236)

Pathology Report